Celularity logo

CelularityNASDAQ: CELU

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 August 2019

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$31.66 M
-98%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector
-94%vs. 3y high
41%vs. sector
-98%vs. 3y high
22%vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$1.44+$0.03(+2.13%)

Dividend

No data over the past 3 years
$14.68 M-$22.01 M

Analysts recommendations

Institutional Ownership

CELU Latest News

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
globenewswire.com23 October 2024 Sentiment: POSITIVE

Celularity common stock and warrants will continue to trade on The Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively Celularity common stock and warrants will continue to trade on The Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal
globenewswire.com18 October 2024 Sentiment: NEGATIVE

FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that it has received a formal notice from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) on October 16, 2024, indicating that the Company is subject to delisting due to its inability to timely file its Forms 10-Q for the the periods ended March 31, 2024, and June 30, 2024 (the “Forms 10-Q”) within the prescribed 180-day compliance period. Nasdaq's notice has no immediate effect on the listing of the Company's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW”, respectively.

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
globenewswire.com16 October 2024 Sentiment: POSITIVE

FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of placental-derived advanced biomaterial products with the acquisition of Rebound, a full thickness placental-derived allograft matrix product, from Sequence LifeScience, Inc. (“Sequence”).

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference
globenewswire.com05 September 2024 Sentiment: POSITIVE

FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024.

Celularity Appoints Richard J. Berman to its Board of Directors
globenewswire.com28 August 2024 Sentiment: POSITIVE

Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value Seasoned Public Company Director and Finance Veteran Brings Extensive Track Record of Success in Facilitating the Growth of Shareholder Value

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
globenewswire.com23 August 2024 Sentiment: NEGATIVE

FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc.  (Nasdaq: CELU) (the “Company”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on August 22, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Form 10-Q for the quarter ended June 30, 2024 (“Q2 2024 Form 10-Q”), and because the Company remains delinquent in filing its Form 10-Q for the quarter ended June 30, 2024 (“Q2 2024 Form 10-Q”), it does not comply with the Nasdaq continued listing requirements which require listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq's notice has no immediate effect on the listing of Celularity's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW”, respectively.

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
globenewswire.com24 May 2024 Sentiment: NEGATIVE

FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc.  (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on May 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Form 10-Q for the quarter ended March 31, 2024 (“Q1 2024 Form 10-Q”), and because the Company remains delinquent in filing its Annual Report on Form 10-K for the year ended December 31, 2023 (“2023 Form 10-K”), does not comply with the Nasdaq continued listing requirements which require listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq's notice has no immediate effect on the listing of Celularity's common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW”, respectively.

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
GlobeNewsWire08 April 2024 Sentiment: NEGATIVE

FLORHAM PARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year's American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit
GlobeNewsWire14 March 2024 Sentiment: POSITIVE

Presentation Will Discuss Cellular Immunotherapy's Potential Role in Treating Chronic Conditions and Extending People's Lives Presentation Will Discuss Cellular Immunotherapy's Potential Role in Treating Chronic Conditions and Extending People's Lives

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
GlobeNewsWire12 March 2024 Sentiment: POSITIVE

Keynote Will Discuss Cellular Immunotherapy's Potential for Treating Chronic Conditions, Including Cancer, Multiple Sclerosis and Parkinson's Disease Keynote Will Discuss Cellular Immunotherapy's Potential for Treating Chronic Conditions, Including Cancer, Multiple Sclerosis and Parkinson's Disease

What type of business is Celularity?

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.

What sector is Celularity in?

Celularity is in the Healthcare sector

What industry is Celularity in?

Celularity is in the Biotechnology industry

What country is Celularity from?

Celularity is headquartered in United States

When did Celularity go public?

Celularity initial public offering (IPO) was on 08 August 2019

What is Celularity website?

https://www.celularity.com

Is Celularity in the S&P 500?

No, Celularity is not included in the S&P 500 index

Is Celularity in the NASDAQ 100?

No, Celularity is not included in the NASDAQ 100 index

Is Celularity in the Dow Jones?

No, Celularity is not included in the Dow Jones index

When was Celularity the previous earnings report?

No data

When does Celularity earnings report?

Next earnings report date is not announced yet